Pembrolizumab combined with carfilzomib and low-dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE-023 study

被引：9
|
作者：
Moreau, Philippe [1 ]
Ghori, Razi [2 ]
Farooqui, Mohammed [2 ]
Marinello, Patricia [2 ]
San Miguel, Jesus [3 ]
机构：
[1] Univ Hosp Hotel Dieu, Dept Hematol, Nantes, France
[2] Merck & Co Inc, Dept Med Oncol, Kenilworth, NJ USA
[3] Clin Univ Navarra, CIMA, IDISNA, CIBERONC,Dept Clin & Translat Med, Pamplona, Spain
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2021年 / 194卷 / 01期
关键词：
multiple myeloma; immunotherapy; oncology; IMMUNOTHERAPY;
D O I：
10.1111/bjh.17448
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E48 / E51
页数：4
相关论文
共 50 条
  • [31] Phase I/II study of bortezomib, lenalidomide, and dexamethasone treatment for relapsed and refractory multiple myeloma
    Mori, Yasuo
    Choi, Ilseung
    Yoshimoto, Goichi
    Muta, Tsuyoshi
    Yamasaki, Satoshi
    Tanimoto, Kazuki
    Kamimura, Tomohiko
    Iwasaki, Hiromi
    Ogawa, Ryosuke
    Akashi, Koichi
    Miyamoto, Toshihiro
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (05) : 673 - 680
  • [32] Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World "POWERFUL" Study
    Terpos, Evangelos
    Repousis, Panagiotis
    Lalayanni, Chrysavgi
    Hatjiharissi, Evdoxia
    Assimakopoulou, Theodora
    Vassilopoulos, Georgios
    Pouli, Anastasia
    Spanoudakis, Emmanouil
    Michalis, Eurydiki
    Pangalis, Gerassimos
    Ntanasis-Stathopoulos, Ioannis
    Poziopoulos, Christos
    Kyrtsonis, Marie-Christine
    Pappa, Vasiliki
    Symeonidis, Argiris
    Georgopoulos, Christos
    Zikos, Panagiotis M.
    Gavriatopoulou, Maria
    Papadaki, Helen A.
    Dadakaridou, Magdalini
    Karvounis-Marolachakis, Kiki
    Katodritou, Eirini
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (07)
  • [33] Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma
    Tsutomu Kobayashi
    Junya Kuroda
    Shin-ichi Fuchida
    Hitomi Kaneko
    Hideo Yagi
    Hirohiko Shibayama
    Hirokazu Tanaka
    Satoru Kosugi
    Nobuhiko Uoshima
    Masayuki Kobayashi
    Yoko Adachi
    Kensuke Ohta
    Kazuyoshi Ishii
    Hitoji Uchiyama
    Mitsuhiro Matsuda
    Eiji Nakatani
    Mitsuru Tsudo
    Chihiro Shimazaki
    Akifumi Takaori-Kondo
    Shosaku Nomura
    Itaru Matsumura
    Masafumi Taniwaki
    Yuzuru Kanakura
    International Journal of Hematology, 2015, 101 : 37 - 45
  • [34] Phase I/II study of bortezomib, lenalidomide, and dexamethasone treatment for relapsed and refractory multiple myeloma
    Yasuo Mori
    Ilseung Choi
    Goichi Yoshimoto
    Tsuyoshi Muta
    Satoshi Yamasaki
    Kazuki Tanimoto
    Tomohiko Kamimura
    Hiromi Iwasaki
    Ryosuke Ogawa
    Koichi Akashi
    Toshihiro Miyamoto
    International Journal of Hematology, 2020, 111 : 673 - 680
  • [35] Carfilzomib 20/45 or 20/56 mg/m2 infused over 30 min in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Badros, Ashraf
    Papadopoulos, Kyriakos P.
    Zojwalla, Naseem
    Ruey, Ju
    Lee, Jiuan
    Siegel, David S.
    LEUKEMIA & LYMPHOMA, 2013, 54 : 17 - 18
  • [36] Phase 1b trial of pembrolizumab monotherapy for relapsed/ refractory multiple myeloma: KEYNOTE-013
    Ribrag, Vincent
    Avigan, David E.
    Green, Damian J.
    Wise-Draper, Trisha
    Posada, Juan G.
    Vij, Ravi
    Zhu, Ying
    Farooqui, Mohammed Z. H.
    Marinello, Patricia
    Siegel, David S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (03) : E41 - E44
  • [37] Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: A retro-prospective observational study
    Del Giudice, Maria Livia
    Gozzetti, Alessandro
    Antonioli, Elisabetta
    Attucci, Irene
    Pengue, Ludovica
    Cassano Cassano, Raffaella
    Ghio, Francesco
    Orciuolo, Enrico
    Simoncelli, Martina
    Bocchia, Monica
    Galimberti, Sara
    Buda, Gabriele
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 109 (04) : 373 - 380
  • [38] Weekly carfilzomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma: A phase 1 and PK/PD trial
    Maruyama, Dai
    Tobinai, Kensei
    Chou, Takaaki
    Taniwaki, Masafumi
    Shumiya, Yoshihisa
    Iida, Shinsuke
    CANCER SCIENCE, 2018, 109 (10): : 3245 - 3252
  • [39] Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study
    Del Giudice, Maria Livia
    Gozzetti, Alessandro
    Antonioli, Elisabetta
    Orciuolo, Enrico
    Ghio, Francesco
    Ciofini, Sara
    Candi, Veronica
    Fontanelli, Giulia
    Attucci, Irene
    Formica, Giuseppe
    Bocchia, Monica
    Galimberti, Sara
    Petrini, Mario
    Buda, Gabriele
    MEDICINA-LITHUANIA, 2021, 57 (09):
  • [40] A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma
    Rocchi, Serena
    Tacchetti, Paola
    Pantani, Lucia
    Mancuso, Katia
    Rizzello, Ilaria
    di Giovanni Bezzi, Chiara
    Scalese, Marco
    Dozza, Luca
    Marzocchi, Giulia
    Martello, Marina
    Barila, Gregorio
    Antonioli, Elisabetta
    Staderini, Michela
    Buda, Gabriele
    Petrini, Mario
    Cea, Michele
    Quaresima, Micol
    Furlan, Anna
    Bonalumi, Angela
    Cavo, Michele
    Zamagni, Elena
    HEMATOLOGICAL ONCOLOGY, 2021, 39 (01) : 41 - 50
12345